Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Buparlisib + Cediranib |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Buparlisib | BKM-120|BKM120 | PI3K Inhibitor (Pan) 43 | Buparlisib (BKM120) specifically inhibits class I PI3K in the PI3K/AKT kinase (or protein kinase B) signaling pathway in an ATP-competitive manner, and may result in apoptotic activity and inhibition of cell proliferation (PMID: 22188813). | |
| Cediranib | AZD-2171|Recentin|AZD2171|AZD 2171 | KIT Inhibitor 57 VEGFR1 Inhibitor 6 VEGFR2 Inhibitor 37 VEGFR3 Inhibitor 6 | Cediranib (AZD-2171) is an ATP-competitive inhibitor of all three vascular endothelial growth factor receptors (FLT1, KDR, and FLT4) and KIT, thereby blocking VEGF-signaling, angiogenesis, and tumor cell growth (PMID: 15899831, PMID: 24714778, PMID: 32444417). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| PIK3CA H1047R | endometrial mixed adenocarcinoma | sensitive | Buparlisib + Cediranib | Preclinical - Pdx & cell culture | Actionable | In a preclinical study, treatment with the combination of Buparlisib (BKM120) and Cediranib (AZD-2171) synergistically inhibited viability of a patient-derived organoid model of endometrial mixed adenocarcinoma harboring PIK3CA H1047R in culture and inhibited tumor growth in a patient-derived xenograft (PDX) model (PMID: 41886729). | 41886729 |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|